The merit of testing gene therapies in different fibrosis models has also been demonstrated by Yoon et al.,67 who explored whether silencing of growth factors amphiregulin (AREG) and cellular communication network factor 2 (CCN2) protected bleomycin-treated and TGF-β1-transgenic mice from fibrosis. This evidence concerns the gene TGFB1 and fibrosis.